Table 3.
Agent | Year introduced | Mechanism of action | MIC90 CNS MSCNS/MRCNS | MIC90S. aureus MSSA/MRSA | Reference |
---|---|---|---|---|---|
Ceftibiprole | N.A. | Binds to abberant penicillin binding protein,PBP-2A | 1.0/2.0 | 0.5/2.0 | Bogdanovich et al 2005a |
Daptomycin | 2003 | Cell membrane lysis | 0.5/0.5 | 0.5/0.5 | Critchley et al 2003,Petersen et al 2002 |
Dalbavancin | N.A. | Blocks cell-wall synthesis like teichoplanin | 0.06/0.06 | 0.06/0.06 | Lin et al 2005 |
Linezolid | 2000 | Binds to tRNA | 4.0/4.0 | 4.0/4.0 | Noskin et al 1999 |
Moxifloxacin | 2002 | Interferes with topoisomerase II and IV | 0.12/4.0 | 0.12/4.0 | Hardy et al 2000 |
Televancin | N.A. | Blocks the synthesis of phospholipids in cell membranes | 0.5/1.0 | 0.5/0.5 | King et al 2004 |
Tigecycline | 2003 | Blocks 30s ribosome | 0.5/0.5 | 0.5/0.5 | Frische et al 2004 Gales et al 2005,Sader et al 2005 |
Abbreviations: CNS, coagulase-negative staphylococci; MSCNS/MRCNS, methicillin-susceptible/methicillin-resistant CNS; MSSA/MRSA, methicillin-susceptible S. aureus/methicillin-resistant S. aureus.